Sungwoo Kang

Mr. Sungwoo Kang

Kyunghee University, Seoul, Republic of Korea
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SKSungwoo Kang
Sungwoo Kang
KKKwan-Il Kim
Kwan-Il Kim
YBYoungmin Bu
Youngmin Bu
BLBeom-Joon Lee
Beom-Joon Lee
HJHee-Jae Jung
Hee-Jae Jung
In traditional Korean medicine, Chungsangboha-tang (CSBHT) and its modified forms are used to treat various respiratory disorders, including asthma. This study aimed to identify research trends, clarify the effectiveness of CSBHT and related prescriptions, and lay a foundation for future research. We conducted a literature review using PubMed, Embase, Google Scholar, Oriental Medicine Advanced Searching Integrated System, National Digital Science Links, Korean Medical Database, Wanfang Data, and Chinese National Knowledge Infrastructure databases. We analyzed 25 studies, including 5 in vitro studies, 6 animal studies, and 14 human studies. Many studies evaluated the efficacy of CSBHT and its related prescriptions, including experimental studies on its effectiveness in asthma. The main mechanism of action involves the anti-inflammatory effect caused by the regulation of various immune cells, cytokines, and chemokines. In addition, clinical trials on asthma reported the benefits of CSBHT and its related prescriptions. However, there has been no randomized controlled study of clinical trials on the clinical effectiveness of CSBHT in asthma. Therefore, large-scale randomized controlled studies should be conducted in the future.

3 December 2024 in Integrative Medicine Research
Verified
Journal Article
Open access
SHSeojung Ha
Seojung Ha
SKSungwoo Kang
Sungwoo Kang
SLSanghoon Lee
Sanghoon Lee
Background: Temporomandibular joint disorders (TMDs) cause pain and functional restrictions in the temporomandibular joint that interfere with daily activities. This study aimed to evaluate and compare the effectiveness and safety of various traditional East Asian medicine treatments, including acupuncture, electroacupuncture, moxibustion, and herbal medicine, in the management of TMD. Methods: We included searches of MEDLINE, CENTRAL, EMBASE, AMED, CINAHL, OASIS, KISS, RISS, KMbase, KCI, CNKI, and CiNii from inception to November 12, 2023, for randomized controlled trials of traditional East Asian medicine treatments in patients with TMD. A network meta-analysis was performed using frequentist methods, and the Confidence In Network Meta-Analysis methodology were employed to assess evidence quality. Results: Forty-five studies with 2,211 participants were finally included. Acupotomy (Mean difference (MD)-5.07, 95 % Confidence interval (CI)-7.37 to-2.78) and acupuncture (MD-1.18, 95 % CI-2.28 to-0.09) showed statistically significant superiority in reducing pain intensity compared to sham treatment. According to the SUCRA rankings, acupotomy was considered the most effective treatment, followed by electroacupuncture, acupuncture, manipulation, laser therapy and occlusal splint. A total of 12 studies reported incidence of adverse events, and none were serious adverse events. Conclusion: Acupotomy and acupuncture could be more beneficial than sham treatment in pain relief and might be a better option than occlusal splint. However, future rigorous, well-designed trials are needed to draw clear conclusions. Protocol registration: PROSPERO (CRD42023467340).

1 December 2023 in Journal of Korean Medicine
Verified
Journal Article
Open access
PDF file
SKSungwoo Kang
Sungwoo Kang
KKKwan-Il Kim
Kwan-Il Kim
MSMideok Song
Mideok Song
JRJinhwan Roh
Jinhwan Roh
NCNamhun Cho
Namhun Cho
BLBeom-Joon Lee
Beom-Joon Lee
Objectives: This retrospective observational study aimed to investigate the efficacy and safety of Cheongpebaedok-tang, a traditional Korean herbal medicine, provided via telemedicine to patients with asymptomatic to mild COVID-19 in Korea.Methods: From February to April 2020, a retrospective analysis investigated COVID-19 patients treated via Korean telemedicine. The study involved asymptomatic to mild cases receiving Cheongpebaedok-tang more than three times, along with continuous Korean medicine care in convalescence. Diagnoses and treatment adhered to the telemedicine guidelines of the Association of Korean Medicine, with varied Cheongpebaedok-tang prescriptions based on symptom severity. Symptom evaluation involved a detailed assessment using a 15-item tool at initial and final sessions.Results: The study included 27 patients, with a mean age of 48.7 ± 2.3 years (mean ± standard error). Patients began self-administering oral Cheongpebaedok-tang for an average of 19.4 ± 1.8 days after the date of COVID-19 diagnosis confirmation and continued the medication for 15.8 ± 1.2 days. The reported side effects of the Cheongpebaedok-tang included palpitations (11.1%), insomnia (7.4%), dizziness (3.7%), and diarrhea (3.7%). All side effects disappeared after adjusting the prescription according to standard treatment guidelines. The occurrence of all COVID-19-related adverse symptoms, except fatigue and myalgia, decreased. Fatigue was the most common chronic symptom persisting after 6 months (51.9%), followed by ocular symptoms (37.0%) and sore throat (22.2%).Conclusions: This study implies Cheongpebaedok-tang may offer a potentially safe, symptom-alleviating approach for managing mild COVID-19 cases via telemedicine, although further comprehensive research is warranted.